Placebo influences on dyskinesia in Parkinson's disease.
about
Emerging approaches in Parkinson's disease - adjunctive role of safinamideEltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.Mechanisms for alternative treatments in Parkinson's disease: acupuncture, tai chi, and other treatments.New small molecules for the treatment of Parkinson's disease.Placebo effects in neurological diseasesNocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis.Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients.Age and sex as moderators of the placebo response – an evaluation of systematic reviews and meta-analyses across medicineParkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Mind matters: placebo enhances reward learning in Parkinson's disease.Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson's DiseaseSuitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.Non-dopaminergic treatments for motor control in Parkinson's disease.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsInteraction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Molecular imaging of levodopa-induced dyskinesias.ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Clinical drug research in chronic central neurodegenerative disorders.Promising therapeutic agents for the treatment of Parkinson's disease.Investigational agents for the management of Huntington's disease.Non-human primate models of PD to test novel therapies.Which dyskinesia scale best detects treatment response?Teaching neurons to respond to placebos.Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships.Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response.Cell transplantation and gene therapy in Parkinson's disease.Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning.Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.Therapy for dyskinesias in Parkinson’s disease patients
P2860
Q26740905-F564317E-EC96-4A9B-8662-6655E4F5C96EQ27303857-53D705B3-FAF6-4FDD-910C-EF28ACF6060BQ30361677-3A6D11A5-C6C9-4076-AA53-A3536B59CAE6Q33636631-F852771D-8010-46A8-B318-E48FEA61CAA6Q34145218-C3D9BB22-7328-4051-933F-176CBBBF4F37Q34311226-BFD9AFC5-D36B-45E2-8FB0-350D7FF03775Q35070472-85AF4528-C28A-42E3-B702-F8C763AD4FE5Q35183919-C7149A1F-15C7-4887-BC28-40864187BC59Q35513153-6E1B93AA-30CA-412E-973F-337EACAB9ACDQ35614156-B7FF3ACB-D8F4-43D4-9BF2-B8CFD4E4DB23Q35854824-976C9584-2D8C-4773-ACA3-EBC06808349BQ37666696-61B34D51-92B7-4CDD-8E46-7D9933C96650Q38103966-9D6E4914-CF22-4765-9C0B-D4C200B82B30Q38126817-AD2323BD-4436-45A6-988F-454DDA894B2FQ38156760-B06C734A-E294-495C-9272-B5F9B49F2308Q38199670-7F71C770-AED7-4132-81B3-880582CF3392Q38246682-FD908B1E-3BC5-4090-A3CB-3E4A0FCB595AQ38262418-16CA8223-5239-4CED-AB97-7194111535C1Q38355582-15E78DA2-D23C-4177-A5CB-80EE7D4563B1Q38375701-A1C57728-369D-4140-8EDF-B3DDE53952C5Q38636630-4FD84437-A4F2-4099-B4FC-B958A240DE6CQ38763831-E97950A8-FDE4-488C-AF32-4907AF624CEBQ38767711-47FB4439-A03E-447A-895E-A04229CB36C7Q39031769-C0F54307-8D44-445D-96A5-DE7BE2F49A20Q39229450-717EFBF6-B37D-4BF9-A725-5E4A29C95ECDQ39471220-A577097A-60C2-4900-B36B-6CE735378F20Q40009826-5257312B-3C57-4BDA-AAE0-937235D39C56Q41184173-F70BFCE8-A09F-4264-809F-C9599139DA5EQ42455819-DC1CBC15-910F-46C7-B085-31AA437B8050Q44297524-07BA2F67-8A31-49DA-8754-6B01F4C1EF78Q45075694-B31D4067-5CC2-4E56-A879-EB743FA3B41BQ48088458-E159EF45-3E3E-460D-9278-84D8B079C7D5Q53410082-DF2BDDC0-BEC5-426B-A1F2-E0A6A283EAC6Q57518128-A44E9719-A33A-483D-BEC8-19F6CBCC189A
P2860
Placebo influences on dyskinesia in Parkinson's disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Placebo influences on dyskinesia in Parkinson's disease.
@en
type
label
Placebo influences on dyskinesia in Parkinson's disease.
@en
prefLabel
Placebo influences on dyskinesia in Parkinson's disease.
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Placebo influences on dyskinesia in Parkinson's disease.
@en
P2093
Christine Hicking
Eugene Laska
Hermann Russ
Philippe Damier
P2860
P304
P356
10.1002/MDS.21897
P407
P577
2008-04-01T00:00:00Z